This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
WORCESTER, Mass. and
June 8, 2012 /PRNewswire/ -- Generex Biotechnology Corporation (OTCBB: GNBT) reported today that the inaugural meeting of the Scientific Advisory Board (SAB) of its wholly-owned subsidiary, Antigen Express, Inc., for the company's AE37 breast cancer vaccine took place in
Dallas, TX on
May 19, 2012.
The following distinguished scientists, scholars, and physicians joined representatives of Generex and Antigen Express at the SAB meeting: Dr.
Kathy D. Miller, MD (
Indiana University School of Medicine Melvin and Bren Simon Cancer Center); Dr.
Ian Krop, MD, PhD (Dana-Farber Cancer Institute,
Harvard Medical School); Dr.
James J. Mule, MD (Moffitt Cancer Centre); Dr.
Keith L. Knutson, PhD (Mayo Clinic); Dr.
Nuhad Ibrahim, MD (MD Anderson Cancer Center); Dr.
Hope S. Rugo, MD (
University of California San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center); and, Dr.
Samuel Jacobs, MD (National Surgical Adjuvant Breast and Bowel Project (NSABP).
Eric von Hofe, PhD, President of Antigen Express, reported: "We had a successful and productive inaugural SAB meeting. We are gratified that these key opinion leaders have recognized the potential of our AE37 breast cancer vaccine and joined with us to maximize the potential for clinical and regulatory success. We have received invaluable input regarding our pending transition into a Phase III clinical trial of the vaccine."
Generex is also proud to announce that the following physicians have joined the SAB:
Dr. Samuel Jacobs, MDDirector, Medical AffairsNational Surgical Adjuvant Breast and Bowel Project (NSABP)
Samuel Jacobs, MD is an emeritus Clinical Professor in the Department of Medicine,
University of Pittsburgh School of Medicine, and the Director of Medical Affairs for the National Surgical Adjuvant Breast and Bowel Project (NSABP). Dr. Jacobs has a long and distinguished career as a clinical researcher in the fields of breast oncology and lymphoma. His recent focus has been in area of developmental therapeutics.
For the last four years, Dr. Jacobs has been intimately involved with the research efforts of the NSABP Foundation, Inc., which has more than 700 research sites in
North America and an international network of oncology and research professionals. The NSABP pioneered breast cancer studies that led to the establishment of lumpectomy plus radiation over mastectomy as the standard surgical treatment for breast cancer and was also the first group to demonstrate that adjuvant therapy (treatment in addition to surgery) could alter the natural history of breast cancer, increase survival rates, and prevent recurrence using chemotherapy as well as hormonal therapies.
In addition to his work in oncology treatment protocols, Dr. Jacobs has also conducted considerable research on the logistics and management of the clinical trial process in oncology. He has led the efforts at the
University of Pittsburgh Clinical Research Service to provide study development and implementation assistance, IRB processing, patient recruitment, study coordination, and specimen and data collection for all investigators conducting cancer-related studies at all UPMC Cancer Centers.
Dr. Jacobs received his MD from the
University of Rochester, and has spent his career making the
University of Pittsburgh Medical Center a leading institution in the field of oncology and cancer management.
With respect to his participation on the SAB, Dr. Jacobs states: "Based on the exciting preliminary Phase II data on the AE37 vaccine in adjuvant treatment of breast cancer, it is possible that this vaccine will have a major impact on the future treatment of a subset of early breast cancer patients. It seems clearly worthwhile to carefully determine its utility in a large well-conducted trial."